for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Fresenius SE & Co KGaA

FREG.DE

Latest Trade

42.85EUR

Change

0.02(+0.05%)

Volume

234,779

Today's Range

42.60

 - 

43.41

52 Week Range

24.25

 - 

51.54

As of on the XETRA ∙ Minimum 15 minute delay

Pricing

Previous Close
42.83
Open
43.13
Volume
234,779
3M AVG Volume
38.69
Today's High
43.41
Today's Low
42.60
52 Week High
51.54
52 Week Low
24.25
Shares Out (MIL)
552.39
Market Cap (MIL)
23,564.13
Forward P/E
12.78
Dividend (Yield %)
1.99

Next Event

Fresenius SE & Co KGaA Annual Shareholders Meeting

Latest Developments

More

Fresenius CEO: Sees Faster Earnings Growth In H2 After Low Point In Q2

Fresenius Sees Constant Currency Net Income Growth Of -4% To +1% in 2020

Fresenius Appoints Sebastian Biedenkopf As Chief Legal And Compliance Officer

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA is a Germany-based healthcare group. It operates through four business segments. Fresenius Medical Care runs a global network of dialysis clinics, providing treatment for patients with chronic kidney failure. It also offers dialyzers, dialysis machines and renal pharmaceuticals. Fresenius Kabi specializes in intravenously administered generic drugs (IV drugs), clinical nutrition and infusion therapies. It also supplies hospitals with medical devices and products of transfusion technology. Fresenius Helios is a private hospital operator, with over 130 facilities in Germany, including maximum care hospitals and rehabilitation centers and, through Quironsalud, over 80 hospitals and outpatient centers, as well as approximately 300 Occupational Risk Prevention Centers in Spain. Fresenius Vamed manages projects and provides services for health care facilities worldwide, from development and turnkey construction to maintenance and total operational management.

Industry

Healthcare Facilities

Contact Info

Else-Kroener-Str. 1

61352

Germany

+49.6172.6080

https://www.fresenius.de/

Executive Leadership

Gerd Krick

Independent Chairman of the Supervisory Board

Stephan Sturm

Chairman of the Management Board, Chief Executive Officer

Michael Diekmann

Independent Deputy Chairman of the Supervisory Board

Niko Stumpfoegger

Independent Deputy Chairman of the Supervisory Board

Rachel Clare Empey

Chief Financial Officer, Member of the Management Board

Key Stats

1.92 mean rating - 24 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2017

33.9K

2018

33.5K

2019

35.4K

2020(E)

37.1K
EPS (EUR)

2017

3.250

2018

3.630

2019

3.440

2020(E)

3.302
Price To Earnings (TTM)
12.91
Price To Sales (TTM)
0.65
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
4.23
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Fresenius beats second-quarter earnings forecasts, cuts 2020 outlook

German healthcare group Fresenius beat second-quarter earnings forecasts on Thursday, helped by the strong performance of its dialysis unit but cut 2020 outlook to account for the continued negative impact of the coronavirus pandemic.

BRIEF-Fresenius Appoints Sebastian Biedenkopf As Chief Legal And Compliance Officer

* SEBASTIAN BIEDENKOPF, CURRENTLY GENERAL COUNSEL OF ROBERT BOSCH GMBH, WILL JOIN THE MANAGEMENT BOARD OF FRESENIUS AS CHIEF LEGAL AND COMPLIANCE OFFICER

BRIEF-Fresenius Helios Acquires Hospital In Western Germany

* FRESENIUS HELIOS IS ACQUIRING THE MALTESER HOSPITAL (“MKHB”) IN THE WESTERN GERMAN CITY OF BONN

BRIEF-Fresenius Says FDA Accepted For Review Kabi's Biologics License Application For Biosimilar MSB11455

* FDA ACCEPTED FOR REVIEW COMPANY`S BIOLOGICS LICENSE APPLICATION (BLA) FOR MSB11455, A BIOSIMILAR CANDIDATE OF NEULASTA® (PEGFILGRASTIM) Source text for Eikon: Further company coverage: (Gdansk Newsroom)

BRIEF-Fresenius Says EMA Accepted Kabi's Submission For Pegfilgrastim Biosimilar For Review

* FRESENIUS KABI'S REGULATORY SUBMISSION FOR PEGFILGRASTIM BIOSIMILAR ACCEPTED FOR REVIEW BY EMA Further company coverage: (Berlin Speed Desk)

BRIEF-Fresenius CEO To FAZ: We Should Be Spared Major Financial Losses During Crisis

* FRESENIUS BOSS SEES WE WILL WEATHER CORONAVIRUS CRISIS WELL - FAZ NEWSPAPER

Fresenius reports first-quarter net income beat on pandemic demand

Healthcare group Fresenius beat first-quarter net income expectations on Wednesday, citing a U.S. and European spike in demand for drugs and devices for COVID-19 patients and government help with costs incurred by health providers.

BRIEF-Fresenius Sees No Impact Of COVID-19 On Dividend Payments

* AKORN DAMAGES CLAIMS: EXPECTS DELAWARE COURT DECISION IMMINENTLY - CONF CALL

BRIEF-Fresenius Says Impact Of Covid-19 On Outlook Cannot Be Assessed

* IMPACT OF COVID-19 ON OUTLOOK CANNOT BE RELIABLY ASSESSED AT THIS TIME

Fresenius reports Q1 net income beat after demand for COVID-19 drugs jumps

German healthcare group Fresenius beat first-quarter net income expectations on Wednesday, citing a spike in demand for drugs and devices for COVID-19 patients in Europe and the United States and German legislation to ease the financial burden on hospitals.

BRIEF-Quva Pharma Voluntarily Recalling All Lots Of R.E.C.K. 50 Ml In Sodium Chloride-60 Ml Bd Syringe Made Using Ketorolac Being Recalled By Fresenius Kabi

* QUVA PHARMA- VOLUNTARILY RECALLING ALL LOTS OF R.E.C.K. 50 ML IN SODIUM CHLORIDE-60 ML BD SYRINGE MADE USING KETOROLAC BEING RECALLED BY FRESENIUS KABI Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Fresenius Postpones 2020 Annual General Meeting

* NEW DATE WILL BE SPECIFIED AND COMMUNICATED AS SOON AS RELIABLE PLANNING IS POSSIBLE

Fresenius: Coronavirus will have negative but not very significant impact on Helios

German healthcare group Fresenius on Friday said the financial impact of the coronavirus pandemic on its Helio Germany hospitals business in 2020 would be negative but not very significant if the outbreak largely subsided by the summer.

Fresenius: Staff, equipment may not suffice for coronavirus peak: WirtschaftsWoche

The chief executive of German healthcare group Fresenius told WirtschaftsWoche magazine that he could not guarantee the German healthcare group's staff and equipment would suffice for the peak of the coronavirus crisis.

Hungary cbanker Nagy flags further steps to help economy

Hungary's economy will need lots of fiscal steps as well to support a V-shaped recovery and the National Bank of Hungary also has further tools at its disposal to use later, Deputy Governor Marton Nagy said on Tuesday.

Fresenius says China drug production back to normal

German healthcare group Fresenius said its generic drugs and infusions unit Kabi had ramped up production in China back to normal levels after government-imposed coronavirus quarantine restrictions were eased.

BRIEF-Fresenius Helios Quirónsalud Hospitals In Spain Remain Fully Operational

* ALL FRESENIUS HELIOS QUIRÓNSALUD HOSPITALS IN SPAIN ARE FULLY OPERATIONAL

BRIEF-Fresenius Says Currently No Reason To Adjust 2020 Guidance Over Coronavirus

* CURRENTLY NO REASON TO ADJUST 2020 GUIDANCE OVER CORONAVIRUS

German hospital firm Asklepios to takeover Rhoen to vie with Fresenius

Unlisted German hospital chain Asklepios outlined plans to take over peer Rhoen Klinikum <RHKG.DE> in a 1.2 billion euro ($1.3 billion) deal, a move that would help it compete with larger rival Helios, a unit of Fresenius <FREG.DE>.

REFILE-BRIEF-Fresenius: FDA Approves Fresenius Medical Care's Novalung

* US FOOD AND DRUG ADMINISTRATION APPROVES FRESENIUS MEDICAL CARE FOR NOVALUNG FOR THE TREATMENT OF ACUTE LUNG AND CARDIOPULMONARY FAILURE

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up